Background:
Multiple pharmacogenomic studies have identified the synonymous genomic variant rs7853758 (G>A, L461L) and the intronic variant rs885004 in SLC28A3 as statistically associated with a lower incidence of anthracycline-induced cardiotoxicity (AIC). However, the true causal variant(s), the cardioprotective mechanism of this locus, the role of
SLC28A3
and other solute carrier (SLC) transporters in AIC, and the suitability of SLC transporters as targets for cardioprotective drugs has not been investigated.
Methods:
Six well-phenotyped, doxorubicin-treated pediatric patients from the original association study cohort were re-recruited and human induced pluripotent stem cell-derived cardiomyocytes were generated. Patient-specific doxorubicin-induced cardiotoxicity (DIC) was then characterized using assays of cell viability, activated caspase 3/7, and doxorubicin uptake. The role of
SLC28A3
in DIC was then queried using overexpression and knockout of
SLC28A3
in isogenic hiPSCs using a CRISPR/Cas9. Fine−mapping of the
SLC28A3
locus was then completed after
SLC28A3
resequencing and an extended in silico haplotype and functional analysis. Genome editing of potential causal variant was done using cytosine base editor.
SLC28A3−AS1
overexpression was done using a lentiviral plasmid-based transduction and was validated using stranded RNA-Seq after ribosomal RNA depletion. Drug screening was done using the Prestwick drug library (
n
= 1200) followed by
in vivo
validation in mice. The effect of desipramine on DOX cytotoxicity was also investigated in eight cancer cell lines.
Results:
Here, using the most commonly used anthracycline, doxorubicin, we demonstrate that patient-derived cardiomyocytes recapitulate the cardioprotective effect of the
SLC28A3
locus and that SLC28A3 expression influences the severity of DIC. Using Nanopore¬-based fine-mapping and base editing we identify a novel cardioprotective SNP rs11140490 in the
SLC28A3
locus which exerts its effect by regulating an antisense long noncoding-RNA (
SLC28A3-AS1
) that overlaps with
SLC28A3
. Using high-throughput drug screening in patient-derived cardiomyocytes and whole organism validation in mice, we identify the SLC competitive inhibitor desipramine as protective against DIC.
Conclusions:
This work demonstrates the power of the human induced pluripotent stem cell model to take a SNP from a statistical association through to drug discovery, providing human cell-tested data for clinical trials to attenuate DIC.
Young at Heart: Pioneering Approaches to Model Nonischaemic Cardiomyopathy with Induced Pluripotent Stem Cells
